Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP340039.RAXI24rwmsDx5g95YcLoTb75qXquNaDDmg7WYGMg7me8Y130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP340039.RAXI24rwmsDx5g95YcLoTb75qXquNaDDmg7WYGMg7me8Y130_provenance.
• NP343183.RAbr1bq42KzySlntTw1CFWauxrYpPGnINFEtNDO9X6Gj4130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP343183.RAbr1bq42KzySlntTw1CFWauxrYpPGnINFEtNDO9X6Gj4130_provenance.
• NP944432.RAWKbd6qd06jLVdwUVB_NX4Pz6dFkE65fBhpKWhBX8Jao130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP944432.RAWKbd6qd06jLVdwUVB_NX4Pz6dFkE65fBhpKWhBX8Jao130_provenance.
• NP754510.RAAdTFVjsG33LYkTGRZiX0PAxEjRPXt17bwjRrxFo8kMM130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754510.RAAdTFVjsG33LYkTGRZiX0PAxEjRPXt17bwjRrxFo8kMM130_provenance.
• NP754493.RAaFHJ_DCwd1hceH3ZR_QybEyUdWG1PD18sPgrI6NtE4o130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754493.RAaFHJ_DCwd1hceH3ZR_QybEyUdWG1PD18sPgrI6NtE4o130_provenance.
• NP754498.RAfXPDpzU67EX-Z5c9FpUZ5V09NdE-Y3K7gKCI6AHJAQQ130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754498.RAfXPDpzU67EX-Z5c9FpUZ5V09NdE-Y3K7gKCI6AHJAQQ130_provenance.
• NP754504.RAaoHdi7LAGR3Oew1LMIVvoXfd6cqFF9WYs_tA66Ql2Cw130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754504.RAaoHdi7LAGR3Oew1LMIVvoXfd6cqFF9WYs_tA66Ql2Cw130_provenance.
• NP754507.RAUO7R7J1LhE_AwKqqTCdnrNLbeYWvX9ExiA1VLLWqV_Q130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754507.RAUO7R7J1LhE_AwKqqTCdnrNLbeYWvX9ExiA1VLLWqV_Q130_provenance.
• NP217790.RAkU8gLmvGgkmorKnN26HOMZ_XdRiHeDe1okBv897_5_s130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217790.RAkU8gLmvGgkmorKnN26HOMZ_XdRiHeDe1okBv897_5_s130_provenance.
• NP438246.RADr2-ffpgLYZRODyNbLeFTYPABwqSJ5rOhcmZbKltd3w130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP438246.RADr2-ffpgLYZRODyNbLeFTYPABwqSJ5rOhcmZbKltd3w130_provenance.
• NP339622.RAmp11xgYH-8cxG1Mb6WgVFnw7wXUhYHaMBBTZf-ccVy0130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP339622.RAmp11xgYH-8cxG1Mb6WgVFnw7wXUhYHaMBBTZf-ccVy0130_provenance.
• NP339866.RAkn2MoDyLK96iUMQto0aIWnuleeg1uxk3ZKkfTZxtM2E130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP339866.RAkn2MoDyLK96iUMQto0aIWnuleeg1uxk3ZKkfTZxtM2E130_provenance.
• NP340653.RAu14Yab3JMkZcoDvBEGEpMCjT92Ye5_uA4pKGgHzpIiE130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP340653.RAu14Yab3JMkZcoDvBEGEpMCjT92Ye5_uA4pKGgHzpIiE130_provenance.
• NP340699.RAqhau4BZtPMqLMyvq3LxQlomNjFrAaaMoUkYdgxb2DgU130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP340699.RAqhau4BZtPMqLMyvq3LxQlomNjFrAaaMoUkYdgxb2DgU130_provenance.
• NP343046.RAtBGBzQvjPMEnf7MA90SS2hH7NMqWCKocUJT4ghExyuI130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP343046.RAtBGBzQvjPMEnf7MA90SS2hH7NMqWCKocUJT4ghExyuI130_provenance.
• NP217640.RAz0E16ksQmsoTPhnZfhzZ7MkUh_hl0brDCz_Ng4NRm_g130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217640.RAz0E16ksQmsoTPhnZfhzZ7MkUh_hl0brDCz_Ng4NRm_g130_provenance.
• NP754500.RAqWP1yYBVNCUDN1pFp3UBTrzGhAnr7VW_vrcg_F2cXQI130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754500.RAqWP1yYBVNCUDN1pFp3UBTrzGhAnr7VW_vrcg_F2cXQI130_provenance.
• NP754502.RAgCTtnp-GdSdCKW_IN0nEQ3-39jV6u86mOvIIVquE0UQ130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754502.RAgCTtnp-GdSdCKW_IN0nEQ3-39jV6u86mOvIIVquE0UQ130_provenance.
• NP951385.RAHqLuJ9b0OspvAfdjeaNsqRPxt2kOnA6gdmuAhj4Jcgg130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP951385.RAHqLuJ9b0OspvAfdjeaNsqRPxt2kOnA6gdmuAhj4Jcgg130_provenance.
• NP951231.RA9Nf67K9K445QT-tuDOjuadelzk9rauqGtvzF73cSU30130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP951231.RA9Nf67K9K445QT-tuDOjuadelzk9rauqGtvzF73cSU30130_provenance.
• NP754495.RAJG1TMhe9OjgugfEbUnaPJeESza4tCp0wnjpmsUW5XUg130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754495.RAJG1TMhe9OjgugfEbUnaPJeESza4tCp0wnjpmsUW5XUg130_provenance.
• NP754508.RAJ-2zVIN5QEW9TOz3ysT-AVsikU0N2JOSQkbrG1Dio6M130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754508.RAJ-2zVIN5QEW9TOz3ysT-AVsikU0N2JOSQkbrG1Dio6M130_provenance.
• NP754509.RAJqead3zgLsot7PHUT1VDd_b-Hy-0gF4mjGXrUAE9iG0130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754509.RAJqead3zgLsot7PHUT1VDd_b-Hy-0gF4mjGXrUAE9iG0130_provenance.
• NP944577.RA21EEnN1zBvDn81yo6R0vom9tA1Z2X4By0Xa0SkAHnTY130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP944577.RA21EEnN1zBvDn81yo6R0vom9tA1Z2X4By0Xa0SkAHnTY130_provenance.
• NP754492.RAxiOMcyJO9l2uHWY-8bkIR_tgPJ0zeisCvWjhNq__vrI130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754492.RAxiOMcyJO9l2uHWY-8bkIR_tgPJ0zeisCvWjhNq__vrI130_provenance.
• NP754496.RAzl-W-APNe-AYMq2yOo1aXI04nmIBStuQRTBDMmziYcE130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754496.RAzl-W-APNe-AYMq2yOo1aXI04nmIBStuQRTBDMmziYcE130_provenance.
• NP754497.RA6pM4ROp_gq8Xzq3Z9FkAcnpdTF37d5VNXRfwdVMBGm0130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754497.RA6pM4ROp_gq8Xzq3Z9FkAcnpdTF37d5VNXRfwdVMBGm0130_provenance.
• NP754501.RAxTpcRRB7QWo47X_ozmxMjDIQ700Mt_8OWjUb05PxrpE130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754501.RAxTpcRRB7QWo47X_ozmxMjDIQ700Mt_8OWjUb05PxrpE130_provenance.
• NP754503.RA_pwMHL5J1VOoqu5OAmrq9jovK1t-0KQkCum76A4sSAY130_assertion description "[We conducted a case-control study, including 209 incident cases with hepatocellular carcinoma (HCC) and two different control groups [275 hospital controls and 381 patients with chronic liver disease (CLD) without HCC], to investigate whether CYP1A1, CYP1A2, CYP2A6, CYP2E1, GSTM1 and NAT2 polymorphisms are related to the risk of HCC with any interaction with cigarette smoking.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754503.RA_pwMHL5J1VOoqu5OAmrq9jovK1t-0KQkCum76A4sSAY130_provenance.